Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...3031323334353637383940...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, HEOR:  Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. (Pubmed Central) -  Aug 18, 2022   
    Our results highlight substantial cost savings achievable by treatment de-escalation, while also reinforcing the importance of therapy breaks to potentially increase tumour responsiveness and reduce treatment toxicity. Our study also highlights how health economic evidence can influence health policy, championing reduced treatment intensity approaches without compromising patient outcomes, which is of particular relevance when addressing the reduced capacity and treatment backlogs experienced during the pandemic.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal:  Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. (Pubmed Central) -  Aug 18, 2022   
    Our study also highlights how health economic evidence can influence health policy, championing reduced treatment intensity approaches without compromising patient outcomes, which is of particular relevance when addressing the reduced capacity and treatment backlogs experienced during the pandemic. These results suggest for the first time that germline polymorphisms in STING and IFNB1 genes may predict the outcomes of cetuximab-based treatment in patients with metastatic colorectal cancer.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, fulzerasib (GFH925) / GenFleet Therap
    New P1 trial, Combination therapy, Metastases:  Efficacy and Safety of IBI351 in Combination With Sintilimab  (clinicaltrials.gov) -  Aug 17, 2022   
    P1,  N=144, Not yet recruiting, 
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date:  MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer (clinicaltrials.gov) -  Aug 16, 2022   
    P=N/A,  N=180, Recruiting, 
    High-quality randomized controlled trial (RCT) studies are required for further validation. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Apr 2022 --> Aug 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
    Trial completion:  ACE-Lung: Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (clinicaltrials.gov) -  Aug 11, 2022   
    P2,  N=118, Completed, 
    Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jun 2024 Unknown status --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tafinlar (dabrafenib) / Novartis, Zelboraf (vemurafenib) / Roche
    Review, Journal:  Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance. (Pubmed Central) -  Aug 11, 2022   
    The use of inhibitors of mutated serine/threonine-protein kinase B-RAF (BRAF), e.g., vemurafenib and dabrafenib, has revolutionized melanoma chemotherapy...One of the proteins responsible for this process is epidermal growth factor receptor (EGFR). In this review, we summarize the role of EGFR signaling in the multidrug resistance of melanomas and discuss possible applications of EGFR inhibitors to overcome the development of drug resistance in melanoma cells during therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial termination:  Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 (clinicaltrials.gov) -  Aug 9, 2022   
    P1/2,  N=13, Terminated, 
    Additionally, this compound achieves modest cetuximab-independent and mutant-selective cellular efficacies on the L858R and L858R/T790M variants. N=30 --> 13 | Recruiting --> Terminated; The study was prematurely closed in December 2021 due to low accrual.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies. (Pubmed Central) -  Aug 7, 2022   
    The lead payload, FGX8-46 (6), produces sequence-selective G-A cross-links and affords cytotoxicity in the low picomolar region across a panel of 11 human tumour cell lines. When conjugated to the antibody cetuximab at an average Drug-Antibody Ratio (DAR) of 2, an ADC is produced with significant antitumour activity at 1 mg/kg in a target-relevant human tumour xenograft mouse model with an unexpectedly high tolerability (i.e., no weight loss observed at doses as high as 45 mg/kg i.v., single dose).
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance. (Pubmed Central) -  Aug 7, 2022   
    The evolved cetuximab variants (Ctx-VY, Ctx-Y104D and Ctx-W52D) with one or two amino acid substitutions in the complementarity-determining region inherit the optimized physical and chemical properties of cetuximab to a great extent, thus ensuring their druggability. Our data collectively show that structure-guided and phage-assisted evolution is an efficient and general approach for reversing receptor mutation-mediated resistance to therapeutic antibody drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    A Toll-Like Receptor agonist represents a potential adjuvant in fourth generation CAR-T cell-based immunotherapy () -  Aug 6, 2022 - Abstract #ITOC2022ITOC_125;    
    A second generation CAR was synthetized (cetuximab scFv - CD8 hinge - 4.1BB - CD3z) and cloned in the MSCV retroviral vector...Conclusions EGFR-targetedCAR-T cells activity, ligand-dependent TLR stimulation and NFAT synTATA inducible protein production represent valuable building blocks for the production of 4 th generation CAR-T cells. Next steps contemplate the construction of a vector encoding for both CAR and inducible TLR ligand, and to test its functionality in terms of improved CAR activity and reshaping of immune cell landscape in solid tumors both in vitro and in an immunocompetent mouse tumor model.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  SNAI1-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patients. (Pubmed Central) -  Aug 6, 2022   
    Finally, a series of 531 patients (TCGA) with CRC was used to assess the role of SNAI1 expression in patients' prognosis indicating an association between tumor SNAI1 expression and overall survival in colon cancer patients but not in rectal cancer patients. SNAI1 expression in CRC cancer patients, together with in vitro experimentation, suggests the possible use of SNAI1 expression in tumor-associated fibroblasts as a predictive biomarker of response to oxaliplatin and cetuximab treatments in patients with CRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using Tc-MAG-Cet-F(ab')-Based SPECT/CT Imaging. (Pubmed Central) -  Aug 6, 2022   
    This study is aimed at investigating the feasibility of cetuximab (Cet) F(ab') fragment- (Cet-F(ab')-) based single photon emission tomography/computed tomography (SPECT/CT) for assessing the epidermal growth factor receptor (EGFR) expression in digestive tumor mouse models...The Tc-MAG-Cet-F(ab')-based SPECT/CT imaging revealed rapid and sustained tracer uptake in MGC803 tumors rather than in HT29 tumors with high image contrast, which was consistent with the results in vitro. SPECT/CT imaging using Tc-MAG-Cet-F(ab') enables the evaluation of the EGFR expression in murine EGFR-positive tumors, indicating the potential utility for noninvasive evaluation of the EGFR expression in tumors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Aug 5, 2022   
    P2,  N=74, Active, not recruiting, 
    SPECT/CT imaging using Tc-MAG-Cet-F(ab') enables the evaluation of the EGFR expression in murine EGFR-positive tumors, indicating the potential utility for noninvasive evaluation of the EGFR expression in tumors. Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Monotherapy, Metastases:  Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 4, 2022   
    P2,  N=3, Terminated, 
    Trial primary completion date: May 2022 --> Dec 2022 N=60 --> 3 | Trial completion date: Feb 2023 --> Dec 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Dec 2021; By Merck